• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

What Scientific & Regulatory Roadblocks Exist for Developing Stem Cell Therapies for the CNS?

Posted on: Friday, 22 December 2006, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c47623) has announced the addition of the Decision Resources, Inc report: New Options for Treating Neurological Disease: Stem Cell Therapy to their offering.

Stem cell therapy development is challenged by controversy, intellectual property issues, and a high failure rate. Despite these challenges, stem cell therapy presents some of the most promising options for hard-to-treat and highly degenerative neurological diseases.

Get the Answers You Need to Shape Your Strategy

Stem cell therapy holds vast potential for treating degeneration or injury in areas of the body that are incapable of autonomous healing, such as the central nervous system (CNS). How can stem cells boost healing in the CNS? What are the limitations of these therapies in the CNS? What scientific and regulatory roadblocks exist for developing stem cell therapies for the CNS?

Several manufacturers are investigating stem cell therapies to treat neurological disease. What are the different approaches for developing these therapies? What value do different stem cell therapies offer, and what challenges do they face? How might these agents impact the different disease markets?

Stem cell therapies may represent the first true disease-modifying therapies for multiple neurological diseases, but their success will depend on many factors, including ethics, clinical trial design, and safety concerns. How are ethics affecting stem cell design? What can we expect from future stem cell clinical trials? Which stem cell therapies are likely to offer the best safety profiles?

Scope

Stem cell introduction: stages of stem cell differentiation, comparison of stem cell types, history of stem cell development.

Value of stem cells for neurological diseases: benefits and limitations of stem cells and their therapeutic value for multiple neurological indications, including Alzheimer's disease and Parkinson's disease.

Emerging stem cell therapies for neurological uses: discussion of multiple companies' initiatives into developing neurological stem cell therapies.

Outlook: hurdles for stem cell therapy development, discussion of which stem cell therapies are more likely to succeed.

Topics Covered

Contents

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Overview of Stem Cell Development

History of Stem Cell Research

Potential of Stem Cell Therapies in Neurological Disease

Stroke 9

Alzheimer's Disease

Parkinson's Disease

Spinal Cord Injury

Multiple Sclerosis

Huntington's Disease

Amyotrophic Lateral Sclerosis

Lysosomal Storage Diseases

Leading Companies in Stem Cell Therapeutics for Neurological Disease

StemCells

Geron

ReNeuron Group

Stem Cell Therapeutics

Athersys

BrainStorm Cell Therapeutics

Advanced Cell Technology

Saneron CCel

Outlook

Tables

1. Types of Stem Cells

2. Neurological Disorders That May Benefit from Stem Cell Therapy

3. Key Research Studies on Stem Cells in Stroke

4. Key Research Studies on Stem Cells in Alzheimer's Disease

5. Key Research Studies on Stem Cells in Parkinson's Disease

6. Key Research Studies on Stem Cells in Spinal Cord Injury

7. Companies Developing Stem Cell Therapies

Figures

1. Stem Cell Differentiation

2. Important Events in the History of Stem Cell Research

3. Government Policies Regarding Stem Cell Research

Companies Mentioned

- Advanced Cell Technology -- Athersys -- Berlex - Boehringer Ingelheim - BrainStorm Cell Therapeutics - Ferrer Internacional -- Genentech -- Geron - Kyowa Hakko - Mitsubishi Pharma - ReNeuron Group - Saneron CCel - Sanofi --Aventis - Schering - Stem Cell Therapeutics - StemCells - Titan Pharmaceuticals

For more information visit http://www.researchandmarkets.com/reports/c47623.

Source: Business Wire

More News in this Category